Shares of Precision BioSciences DTIL were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 61.54% year over year to ($0.63), which missed the estimate of ($0.59).
Revenue of $1,078,000 decreased by 80.00% from the same period last year, which missed the estimate of $4,390,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Technicals
52-week high: $23.67
52-week low: $4.60
Price action over last quarter: down 8.63%
Company Profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.